agribiotechnology

agribiotechnology

[‚ag·rə¦bī·ō‚tek′näl·ə·jē]
(agriculture)
Biotechnology applied to agriculture.
References in periodicals archive ?
International Workshop for Islamic Scholars on Agribiotechnology, Shariah Compliance.
Examples of innovative Israeli agritech includes advanced precision farming techniques, water optimization, robotics and sensor driven technology, environmentally-friendly agrochemicals for crop protection and agribiotechnology.
2) National Laboratories for Agribiotechnology, China Agricultural University, Beijing 100094, China.
Dow AgroSciences' global agriculture presence and its Indianapolis headquarters serve to "advance Indiana as an active region working on new innovation, agribiotechnology, jobs and technologies," says Pete Siggelko, vice president for plant genetics and biotechnology.
The Grocery Manufacturers of America are pressing for reforms in agribiotechnology, but activists believe that the incident warrants a moratorium on all pharming experiments.
headquartered in Boulder, Colorado, is a biopharmaceutical company focussed on the development, production and licensing of complex natural-product pharmaceuticals as well as the development and licensing of novel genetic technologies for applications in agribiotechnology, pharmacogenomic, and human therapeutic and diagnostic applications.
is a pharmaceutical company focused in two distinct research, development and marketing areas: the development and in-licensing of novel pharmaceutical products, primarily in the area of anti-cancer agents, and the development of novel genomic technologies, primarily in the area of "gene editing," for application in human therapeutics, diagnostics, agribiotechnology, and pharmacogenomics.
is a Lilly spin-off and agribiotechnology player Dow AgroSciences formerly was a Lilly joint venture.
is a pharmaceutical company focused in two distinct research, development and marketing areas: the development and in-licensing of novel pharmaceutical products, primarily in the area of anti-cancer agents, and the development of novel genomic technologies primarily in the area of "gene editing," for applications in human therapeutics, diagnostics, agribiotechnology, and pharmacogenomics.
Such statements involve risks and uncertainties including, but not limited to, risks associated with development of the gene editing and agribiotechnology businesses, including competition from companies in similar businesses, limitations on the ability to market products because of the intellectual property rights of third parties, the ability to obtain, maintain and enforce patents, and the risk that developments in the company's business will require new investment.
is a life science company focused in two distinct areas: the development and in-licensing of anti-cancer agents and the development of genomic therapies, primarily through the use of "gene editing" with additional applications in diagnostics, pharmacogenomics, and agribiotechnology.
is a pharmaceutical company focused in two distinct research and marketing areas: the development and in-licensing of novel pharmaceutical products, primarily in the area of anti-cancer agents and the development of novel genomic technologies predominantly in the area of "gene editing" for applications in human therapeutics, diagnostics, agribiotechnology and pharmacogenomics.